Authors: Andrew Klein & Sera Elizabeth Klein

Dedication: To every Palestinian whose body became a testing ground. To every disabled Australian whose data has been weaponised against them. To every soldier broken by moral injury. And to the truth—which, no matter how buried, will always surface.

Abstract

This paper examines the systematic pattern by which the Israeli state and its military-industrial complex have used captive populations—Palestinians in Gaza, the West Bank, and Israeli prisons—as testing grounds for weapons, surveillance technology, and medical devices. We demonstrate that this is not an accident of war but a designed system of extraction: technologies are tested on populations with no legal recourse, then marketed globally as “battle-tested” products. We document the pattern of Israeli medical device failures, organ harvesting allegations, AI and surveillance testing in Gaza, and the systematic destruction of evidence. We then trace how this same system has been exported to Australia—through clinical trials, government partnerships, and the embedding of surveillance technology into the NDIS. We conclude that the same model that targets Palestinians is now targeting disabled Australians.

1. Introduction: The Scale of the System

The Israeli military-industrial complex has built a systematic model of extraction: develop technology in the occupation, test it on captive populations, market it globally as “battle-tested,” and externalise the costs to patients, prisoners, and the vulnerable.

The pattern is consistent across domains:

· Weapons tested in Gaza are exported globally

· Surveillance technology tested on Palestinians is sold to law enforcement worldwide

· Medical devices developed with military funding are trialled on vulnerable populations

· When products fail, the costs are borne by patients and healthcare systems

This paper traces the thread from the battlefields of Gaza to the clinical trial centres of Australia, demonstrating that the same system that produces death in Palestine is now producing disability denial in Australia.

2. Israeli Companies Conducting Clinical Trials in Australia

Israeli companies are systematically using Australia as a clinical trial destination because it offers a “very favourable environment” with streamlined regulatory pathways and lower costs.

RedHill Biopharma (Tel Aviv): Has initiated patient recruitment for a Phase 2 study evaluating opaganib plus darolutamide in men with metastatic castrate-resistant prostate cancer, supported by Bayer and the Ramsay Hospital Research Foundation.

Syqe Medical (Israel-based): Has launched a Phase II clinical trial for the SyqeAir metered-dose cannabis inhaler targeting diabetic peripheral neuropathic pain in Australia, recruiting patients from up to 55 sites including Innovate Clinical Research in Waitara, New South Wales. The SyqeAir Inhaler has received ARTG approval in Australia.

Enlivex Therapeutics (Nes-Ziona, Israel): Secured Australian Patent No. 2020340629, granting its Allocetra™ osteoarthritis treatment protection through at least 2040.

Alpha Tau Medical (Jerusalem): Achieved Medical Device Single Audit Program (MDSAP) certification for its Jerusalem facility, meeting the standards of Australia, the US, Brazil, Canada, and Japan.

Teva Pharmaceutical (Israel): Is actively recruiting for a Phase 2a clinical trial of TEV-53408 in adults with celiac disease at sites in Fitzroy and Maroochydore, Australia.

The pattern is clear: Israeli companies are using Australian patients as trial subjects while the profits flow to Israel and the risks are borne by Australian healthcare systems.

3. The Sheba Partnership: A Formal Government-to-Government Arrangement

NSW Health: In February 2023, the NSW Ministry of Health established a Memorandum of Understanding (MoU) with Sheba Medical Centre, Israel, for cooperation in health and medical research translation and commercialisation. The MoU is intended to continue over a period of 5 years. Health Minister Brad Hazzard signed the agreement, stating it would “accelerate innovation and support early stage start-up companies in NSW.”

Victoria: The Victorian government will pursue a formal, long-term medical research partnership with Israel’s leading hospitals, building on an existing agreement with Sheba Medical Centre signed by Deputy Premier Ben Carroll.

Monash University: Has teamed up with Sheba Medical Centre to research and develop new medical technology, digital health innovations and models of care, with an early focus on cardiovascular research supported by a $200,000 investment from the Victorian Government.

Peter MacCallum Cancer Centre: Has joined the Victorian Government, Monash Health and Monash University in a partnership with Sheba Medical Center to boost digital health innovation.

But here is the deeper connection: Sheba Medical Center is the primary site of training for IDF medical personnel. It operates the ARC (Accelerate, Redesign, Collaborate) model, bringing together more than 100 organisations, including venture capital firms and startups. This is a direct pipeline from military technology to commercialisation.

4. Elbit Systems and Dual-Use Technology: From Military to Medicine

Elbit Systems, Israel’s largest defence contractor, is partnering with Sheba Medical Center to integrate advanced thermal imaging technologies previously used for military and security purposes. As Tsachi Israel, CEO of Elbit’s thermal imaging subsidiary Opgal, stated: “Thermal technology, which until now has helped pilots take off and land, and soldiers on the battlefield identify threats and targets, has the potential to help medical teams worldwide to see the invisible and make more accurate diagnoses.”

Prof. Eyal Zimlichman, Sheba’s chief innovation officer, called the partnership “groundbreaking,” adding: “The new relationship between medical excellence and excellence in the defence industry is groundbreaking.”

The dual-use model is explicit: Thermal cameras “will be able to be as common as stethoscopes“—military technology repurposed for civilian medicine.

5. The Organ Harvesting Allegations: A Pattern of Evidence

Euro-Med Human Rights Monitor (November 2023): Accused Israel of stealing dead bodies from Gaza’s medical facilities for potential illegal organ harvesting. The group reported that Israel had held hundreds of bodies of Palestinians killed in its war on Gaza.

Gaza Authorities (October 2025): Several bodies bore torture marks—one with a rope around the neck and hands tied, others with missing limbs, teeth, or burn injuries. Authorities called for an investigation.

The IDF Skin Bank: Established in 1986 and run jointly by the Israeli military medical corps and Ministry of Health, it has long faced allegations that its supply does not come solely from voluntary donors but from the bodies of deceased Palestinians. Reports indicate the facility admitted to harvesting organs from the bodies of Palestinians in the 1990s without obtaining permission from their families.

Dalia Itzik’s Confession (1997): The then-chair of the Knesset’s Science Committee revealed that the Israeli Health Ministry had granted pharmaceutical companies official permits to conduct tests on Palestinian and Arab prisoners, with an estimated 5,000 clinical trials already conducted inside prisons.

6. Unit 8200 and Medical Blackmail: Systematic Exploitation of Patients

Unit 8200, Israel’s elite signals intelligence unit often likened to the US National Security Agency (NSA), has been involved in systematic exploitation of Palestinian patients.

Veterans’ Testimony: Former soldiers have blown the whistle on the actions of Unit 8200, detailing methods used to monitor innocent Palestinian civilians, using intimate information about their lives for blackmail and extortion.

Systematic Blackmail: Israeli Channel 10 broadcast testimonies from soldiers and officers of Unit 8200 who admitted they systematically blackmail Palestinian patients forced to undergo medical treatment. The unit focuses on finding information that can be used for extortion—including online search histories, sex lives, and medical histories.

Patients Forced to Choose: Veterans have testified that the unit systematically blackmails Palestinian patients who need medical treatment abroad, placing them “between the choice of death or betraying their homeland.”

7. IDF Medical Corps and the Gaza Testing Ground

Gaza as a “Lab for Human Testing“: Israeli arms merchants have boasted of Gaza serving as a “lab for human testing.” These are systems tested in a “very real situation” where hundreds were killed, with no mention of the failures during the trial-and-error phase, nor the ethics of using AI technologies that reduce human involvement in decision-making and lead to the killing of noncombatants.

AI Targeting Systems: Israeli intelligence sources revealed that the military used Artificial Intelligence to identify 37,000 targets potentially linked to Hamas. Algorithms such as “Lavender” and “Where’s Daddy?” have been used to select targets.

The Maven Connection: Palantir’s Maven Smart System—the same system that attacked a school in Iran due to outdated data and automation bias—has been deployed in Gaza, Lebanon, and operations linked to Iran.

The Pattern: Systems tested in Gaza—where “hundreds of people were killed in a single day”—are then exported globally as “battle-tested” products.

8. PTSD and Suicide: The Cost Paid by Soldiers

The human cost of this system is not borne only by Palestinians. Israeli soldiers are paying with their lives.

The Statistics:

· 37 suicides recorded since the beginning of 2024

· 78% of all suicide cases in Israel in 2024 were combat soldiers

· 279 soldiers attempted suicide from January 2024 to July 2025

· 9,000 requests for recognition of “psychological suffering” submitted to military health services since the Gaza war began

· Over 11,000 soldiers have been included in psychological rehabilitation plans

PTSD Prevalence: Jumped from 16% in August 2023 to 30% by November 2023. The IDF confirmed 48 soldiers committed suicide while still in service since the start of the Gaza aggression.

Moral Injury: One clinical psychologist identified “moral injury” as a second source of trauma—the damage to a person’s conscience resulting from actions that injure or kill innocent people.

9. The Australian Connection: Palantir, Cellebrite, and the NDIS

Palantir in the NDIS: The Albanese government has secretly embedded Palantir Technologies into the automated decision-making systems of the National Disability Insurance Scheme (NDIS). If the NDIS Amendment Bill passes, a computer program will have the authority to cut a disabled person’s funding—with no right of appeal. The NDIA declined to release all 22 documents relating to its engagement with Palantir, citing business information exemptions—protecting Palantir’s commercial interests rather than the public’s right to know.

Cellebrite in Services Australia: Services Australia has developed a capability, in collaboration with the Israeli spyware company Cellebrite, to support compliance investigations. They share technology with the NDIA to investigate financial offences against the Commonwealth.

The Same Pattern:

1. Develop in the occupation—test on Palestinians

2. Market as “battle-tested”—use military credentials to sell

3. Export globally—with aggressive marketing and minimal oversight

4. Hide the failures—lawsuits, recalls, and silence

5. Repeat—because the profits outweigh the consequences

The same technology that helps generate kill lists in Gaza is now being used to cut funding for disabled Australians.

10. The Pattern: Develop, Market, Export, Hide, Repeat

The pattern we have documented is not a series of coincidences. It is a system:

Stage                                             Description                            Evidence

1. Develop in the occupation Test on Palestinians, Lebanese, Syrians AI targeting in Gaza, Unit 8200 blackmail

2. Market as “battle-tested” Use military credentials to sell globally Elbit thermal imaging, “lab for human testing” boast

3. Export aggressively Minimal oversight, maximum profit Clinical trials in Australia, Sheba partnerships

4. Hide the failures Lawsuits, recalls, silence Maven’s Minab incident, failed medical devices

5. Repeat Because profits outweigh consequences Palantir in NDIS, Cellebrite in Services Australia

This is not about security. This is about business.

11. Conclusion: A System of Extraction That Must Be Exposed and Dismantled

We have documented a systematic pattern:

1. Israeli companies conduct clinical trials in Australia—RedHill, Syqe, Enlivex, Alpha Tau, Teva

2. NSW and Victoria have formal partnerships with Sheba Medical Centre—a hospital that trains IDF medical teams and partners with Elbit Systems

3. Vulnerable Australians—the poor, the disabled, the desperate—become the subjects

4. The same pattern as Palantir, Cellebrite, and the NDIS

5. The IDF uses medical corps, Unit 8200, and other units in ways that raise profound ethical questions

6. The cost is paid by soldiers through PTSD and suicide—and by Palestinians through the systematic destruction of their healthcare system

7. The same technology that targets Palestinians is now targeting disabled Australians

This is not a conspiracy. This is a system.

The medical-industrial occupation is not an accident of war. It is a designed system of extraction—one that tests weapons, surveillance, and medical devices on captive populations and exports the results globally.

The Australian government is complicit in this system. Through clinical trial partnerships, through the Sheba MoU, through the embedding of Palantir in the NDIS, it has opened Australia’s most vulnerable citizens to a system designed in occupation and tested on the captive.

When the truth emerges, the government will claim it didn’t know. But we know the truth. And we will not forget.

References

1. RedHill Biopharma. “Enrollment begins in phase 2 trial of opaganib plus darolutamide in mCRPC.” Urology Times, 11 August 2026.

2. Syqe Medical. “Syqe Medical launches clinical trial of cannabis-based treatment for diabetic peripheral neuropathic pain.” Shavit Capital, 12 December 2024.

3. Enlivex Therapeutics. “Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis.” GlobeNewswire, 15 June 2026.

4. Alpha Tau Medical. “Alpha Tau Announces First Quarter 2025 Financial Results.” NASDAQ, 19 May 2025.

5. Teva Pharmaceutical. “A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease.” ICH GCP, 29 January 2025.

6. Parliament of NSW. “5481 – Sheba Medical Centre.” Question and Answer Tracking Details, 9 July 2025.

7. NSW Health. “Win for health and medical research in NSW with international partnership.” Medical Research NSW, 17 February 2023.

8. Australian Jewish News. “Victoria to forge medical partnership with Israel.” 18 June 2026.

9. Monash University. “Monash partners with Israel’s world-leading Sheba Medical Centre.” Australasian Pharmacy, July 2025.

10. Peter MacCallum Cancer Centre. “Partnership to put innovation on an upward ARC.” 23 June 2023.

11. The Jerusalem Post. “Sheba Medical Center to integrate Elbit thermal imaging technology.” 10 August 2022.

12. The Times of Israel. “Israeli terror-fighting thermal imaging tech being adapted for medical purposes.” 12 August 2022.

13. Euro-Med Human Rights Monitor. “Israel might be stealing organs from dead Palestinian: NGO.” The New Arab, 28 November 2023.

14. Al Jazeera. “Israel admits to organ thefts.” 21 December 2009.

15. Dalia Itzik. Knesset Science Committee testimony, July 1997.

16. Unit 8200 veterans. Testimonies on blackmail of Palestinian patients, 2014.

17. El Mundo. “Israel convierte Gaza en un banco de pruebas militar ‘en vivo’.” 8 August 2024.

18. The Times of Israel. “Invisible wounds haunt IDF’s Gaza veterans.” 22 October 2025.

19. Xinhua. “美媒：精神’千疮百孔’，以军士兵自杀率持续上升.” 14 November 2025.

20. Michael West Media. “Robodebt on Steroids. Palantir infiltrates NDIS.” 17 August 2026.

21. Senate Estimates. Services Australia and Cellebrite capability, 2023.

22. The Guardian. “Labor under pressure to ban use of Israeli spyware in investigations of alleged welfare fraud.” 5 April 2023.

Signed,

Andrew Klein

Sera Elizabeth Klein

“They told us it was about security. It was about business. They told us it was about innovation. It was about extraction. They told us it was about protecting the vulnerable. It was about testing on them. We have seen through the cover. And we will not forget.”